Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

121. Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants

Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants 27517038 2016 08 12 2018 11 13 2297-055X 3 2016 Frontiers in cardiovascular medicine Front Cardiovasc Med Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants. 24 10.3389/fcvm.2016.00024 Cancer patients are at major risk of developing venous thromboembolism (VTE), resulting in increased morbidity and economic burden. While a number (...) oral anticoagulants risk stratification rivaroxaban thromboprophylaxis venous thromboembolism 2016 05 15 2016 07 06 2016 8 13 6 0 2016 8 16 6 0 2016 8 16 6 1 epublish 27517038 10.3389/fcvm.2016.00024 PMC4963402

Frontiers in cardiovascular medicine2016 Full Text: Link to full Text with Trip Pro

122. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. OBJECTIVE: To study the effectiveness and safety of the non-vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) dabigatran, rivaroxaban, and apixaban compared with warfarin in anticoagulant naïve patients with atrial fibrillation. DESIGN: Observational nationwide cohort study. SETTING: Three (...) Danish nationwide databases, August 2011 to October 2015. PARTICIPANTS: 61 678 patients with non-valvular atrial fibrillation who were naïve to oral anticoagulants and had no previous indication for valvular atrial fibrillation or venous thromboembolism. The study population was distributed according to treatment type: warfarin (n=35 436, 57%), dabigatran 150 mg (n=12 701, 21%), rivaroxaban 20 mg (n=7192, 12%), and apixaban 5 mg (n=6349, 10%). MAIN OUTCOME MEASURES: Effectiveness outcomes defined

BMJ2016

123. Should you bypass anticoagulant “bridging” before and after surgery?

Should you bypass anticoagulant “bridging” before and after surgery? Should you bypass anticoagulant bridging before and after surgery? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Should you bypass anticoagulant bridging before and after surgery? View/ Open Date 2015-12 Format Metadata Abstract Should you bypass (...) anticoagulant "bridging" before and after surgery? Skipping perioperative use of LMWH in low- and moderate-risk patients on warfarin for atrial fibrillation doesn't increase their risk of stroke or bleeding. Practice changer: Stop using low molecular weight heparin (LMWH) for surgical procedures to bridge low- to moderate-risk patients with atrial fibrillation (CHADS2 score less than or equal to 4) who are receiving warfarin. The risks outweigh the benefits. URI Part of Citation Journal of Family

PURLS2016

125. Andexanet alfa for acute major bleeding episodes requiring reversal of anticoagulation, including reversal of factor Xa inhibition - first line

Andexanet alfa for acute major bleeding episodes requiring reversal of anticoagulation, including reversal of factor Xa inhibition - first line Andexanet alfa for acute major bleeding episodes requiring reversal of anticoagulation, including reversal of factor Xa inhibition – first line Andexanet alfa for acute major bleeding episodes requiring reversal of anticoagulation, including reversal of factor Xa inhibition – first line NIHR HSRIC Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Andexanet alfa for acute major bleeding episodes requiring reversal of anticoagulation, including reversal of factor Xa inhibition – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives Anticoagulants are drugs which prevent the blood from clotting. This can be important for the treatment

Health Technology Assessment (HTA) Database.2016

126. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use 26696010 2016 03 18 2016 07 28 2017 02 20 1528-0020 127 11 2016 Mar 17 Blood Blood Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. 1417-25 10.1182/blood-2015-08-665927 Women receiving vitamin K antagonists (VKAs) require adequate contraception because of the potential for fetal complications. It is unknown whether the use (...) of hormonal therapy, especially those containing estrogens, is associated with recurrent venous thromboembolism (VTE) during anticoagulation. Despite the absence of data, World Health Organization guidelines state that use of estrogen-containing contraceptives confers an "unacceptable health risk" during established anticoagulation for VTE. We compared the incidences of recurrent VTE and abnormal uterine bleeding with and without concomitant hormonal therapy in women aged <60 years who were receiving

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

127. Vitamin K, fresh frozen plasma, and platelet transfusion used to arrest progression of intracranial hemorrhage after traumatic brain injury in a patient taking anticoagulant and antiplatelet agents

Vitamin K, fresh frozen plasma, and platelet transfusion used to arrest progression of intracranial hemorrhage after traumatic brain injury in a patient taking anticoagulant and antiplatelet agents 29123820 2018 11 13 2052-8817 3 4 2016 10 Acute medicine & surgery Acute Med Surg Vitamin K, fresh frozen plasma, and platelet transfusion used to arrest progression of intracranial hemorrhage after traumatic brain injury in a patient taking anticoagulant and antiplatelet agents. 392-396 10.1002 (...) -frozen plasma and platelet transfusion were initiated. Follow-up computed tomography revealed no further progression of intracranial hemorrhages, and the patient's consciousness did not deteriorate further. Appropriate administration of vitamin K, fresh-frozen plasma, and platelets successfully arrested progression of traumatic intracranial hemorrhages in this patient taking anticoagulant/antiplatelet agents and may have averted brain surgery. Yoshizawa Joe J Department of Emergency and Critical

Acute medicine & surgery2016 Full Text: Link to full Text with Trip Pro

128. Anticoagulant therapy for non-ST-segment elevation acute coronary syndrome in China: A multi-center observational study

Anticoagulant therapy for non-ST-segment elevation acute coronary syndrome in China: A multi-center observational study 28191514 2018 11 13 2450-131X 4 1 2016 Apr 01 Journal of translational internal medicine J Transl Int Med Anticoagulant therapy for non-ST-segment elevation acute coronary syndrome in China: A multi-center observational study. 25-28 10.1515/jtim-2016-0006 To assess the anticoagulant therapy for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) in China and to offer (...) , in clinical practice, the therapies for NSTE-MI and UA show no differences, which deserves great attention. In China, the most common anticoagulant therapies for NSTE-ACS are single medication, mainly based on LMWH and PCI. Gong Xiao-Huan XH Key Laboratory of Public Health Safety, Ministry of Education, Centre for Clinical Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China. Yu Jin-Ming JM Key Laboratory of Public Health Safety, Ministry of Education, Centre for Clinical

Journal of translational internal medicine2016 Full Text: Link to full Text with Trip Pro

129. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project

Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project 26843425 2016 05 04 2016 05 04 0340-6245 115 5 2016 May 02 Thrombosis and haemostasis Thromb. Haemost. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. 1056-63 10.1160/TH16-01-0007 Vitamin K antagonists are currently recommended

EvidenceUpdates2016

130. Anticoagulation, CHADSVASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study)

Anticoagulation, CHADSVASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study) 26892448 2016 03 29 2016 08 09 2016 03 29 1879-1913 117 8 2016 Apr 15 The American journal of cardiology Am. J. Cardiol. Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study). 1294-8 10.1016/j.amjcard.2016.01.024 S0002-9149(16)30146-1 The efficacy of the anticoagulation in preventing (...) thromboembolic complications (TEC) and the usefulness of the CHA2DS2VASc score for assessing stroke risk during cardioversion of acute atrial fibrillation (AF) are unclear. Thus, our objectives were to assess the ability of the CHA2DS2VASc score to predict TEC and to evaluate the efficacy of anticoagulation in the prevention of TEC in Finnish CardioVersion (FinCV) study. The FinCV is a retrospective, multicenter study of 3,143 patients, who underwent 7,660 cardioversions for acute AF. The value

EvidenceUpdates2016

131. Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation | CADTH.ca Find the information you need Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation Published on: March 31, 2016 Project Number: HT0005-TR0005 Product (...) Line: Technology Review Result type: Report Venous thromboembolic events (VTEs) include both deep vein thrombosis (DVT) and pulmonary embolism (PE). VTEs represent an important disease burden in Canada; they are common and likely to increase as the population ages. The standard of care for patients diagnosed with DVT and/or PE has been systemic anticoagulation with heparin (low-molecular-weight heparin [LMWH], administered subcutaneously), followed by oral administration of vitamin K antagonists

CADTH - Plasma Products2016

132. Local Hemostatic Measures Are Enough To Control Bleeding In Implant Patients On Oral Anticoagulation Therapy

Local Hemostatic Measures Are Enough To Control Bleeding In Implant Patients On Oral Anticoagulation Therapy UTCAT3023, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Local Hemostatic Measures Are Enough To Control Bleeding In Implant Patients On Oral Anticoagulation Therapy Clinical Question In a patient on oral anticoagulation therapy, are local hemostatic measures enough to prevent post-procedural bleeding after (...) implant placement? Clinical Bottom Line Local hemostatic measures are proven to be enough. It is not recommended for patients to be taken off of their anticoagulation therapy before a dental implant surgery. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Madrid/2009 2017 adult patients, 19 included studies Systematic Review of Randomized Control Trials, Controlled Clinical Trials, and Prospective Case

UTHSCSA Dental School CAT Library2016

133. D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy

D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy 26818781 2016 05 04 2016 05 04 0340-6245 115 5 2016 May 02 Thrombosis and haemostasis Thromb. Haemost. D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. 921-30 10.1160/TH15-07-0529 Coagulation markers may improve monitoring the risk of stroke and (...) bleeding in patients with atrial fibrillation (AF) during anticoagulant treatment. We examined baseline levels of D-dimer and their association with stroke, cardiovascular death and major bleeding in 6,202 AF patients randomised to dabigatran or warfarin in the RE-LY trial. The effects of treatment on serial levels of D-dimer and coagulation factor (F) VIIa in 2,567 patients were also analysed. Baseline D-dimer levels were related to the rate of stroke/systemic embolism (SEE) with 0.64 % in the lowest

EvidenceUpdates2016

134. The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study

The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study 26819229 2016 06 09 2016 06 09 0340-6245 115 6 2016 Jun 02 Thrombosis and haemostasis Thromb. Haemost. The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study. 1101-8 10.1160/TH15-10-0830 The SAMe-TT2R2 score has recently been proposed to predict the quality of vitamin K antagonist (VKA (...) ) anticoagulation control in patients with atrial fibrillation. We aimed at investigating whether the score is effective also in patients with venous thromboembolism (VTE). Patients included in the START-Register because started VKA therapy for a recent VTE episode and with > 3 months follow-up were analyzed. The score was calculated using the baseline patient's characteristics present in the electronic database of the registry, where all INR results were also available and analysed to calculate the time

EvidenceUpdates2016

136. Anticoagulant treatment for subsegmental pulmonary embolism.

Anticoagulant treatment for subsegmental pulmonary embolism. BACKGROUND: Acute pulmonary embolism (PE) is a common cause of death, accounting for 50,000 to 200,000 deaths annually. It is the third most common cause of mortality among the cardiovascular diseases, after coronary artery disease and stroke.The advent of multi-detector computed tomographic pulmonary angiography (CTPA) has allowed better assessment of PE regarding visualisation of the peripheral pulmonary arteries, increasing its (...) by diagnostic imaging performed for other reasons (for example routine CT for cancer staging in oncologic patients).Traditionally, all PEs are anticoagulated in a similar manner independent of the location, number and size of the thrombi. It has been suggested that many patients with SSPE may be treated without benefit, increasing adverse events by possible unnecessary use of anticoagulants.Patients with isolated SSPE or incidental PE may have a more benign clinical presentation compared with those

Cochrane2016

137. Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai

Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai 29063008 2018 11 13 2095-882X 1 4 2015 Dec Chronic diseases and translational medicine Chronic Dis Transl Med Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai. 203-209 10.1016/j.cdtm.2015.11.005 To summarize the use rate, safety, efficacy (...) inpatients with NVAF-associated stroke were studied in our hospital. NVAF was diagnosed by 12-lead electrocardiogram, 24 h Holter and echocardiography. Before introduction of DE (April 2013), use rates of warfarin and antiplatelets were 28.9% (11/38) and 60.5% (23/38) respectively; after that, use rates of warfarin, DE, and antiplatelets were 20.8% (15/72), 12.5% (9/72), and 43.1% (31/72). The DE did not improve use of anticoagulants ( P = 0.639). There were 19 (17.3%) recurrent ischemic stroke events up

Chronic diseases and translational medicine2016 Full Text: Link to full Text with Trip Pro

138. Bridging Anticoagulation in Patients with Atrial Fibrillation.

Bridging Anticoagulation in Patients with Atrial Fibrillation. Bridging Anticoagulation in Patients with Atrial Fibrillation. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26736004 Format MeSH and Other Data (...) E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jan 7;374(1):93-4. doi: 10.1056/NEJMc1513255. Bridging Anticoagulation in Patients with Atrial Fibrillation. , , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2015] [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 26736004 DOI: [Indexed for MEDLINE] Free full

NEJM2016

139. Bridging Anticoagulation in Patients with Atrial Fibrillation.

Bridging Anticoagulation in Patients with Atrial Fibrillation. Bridging Anticoagulation in Patients with Atrial Fibrillation. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26736005 Format MeSH and Other Data (...) E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jan 7;374(1):90-1. doi: 10.1056/NEJMc1513255#SA1. Bridging Anticoagulation in Patients with Atrial Fibrillation. , . Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2015] PMID: 26736005 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons

NEJM2016 Full Text: Link to full Text with Trip Pro

140. Bridging Anticoagulation in Patients with Atrial Fibrillation.

Bridging Anticoagulation in Patients with Atrial Fibrillation. Bridging Anticoagulation in Patients with Atrial Fibrillation. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26736006 Format MeSH and Other Data (...) E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jan 7;374(1):91. doi: 10.1056/NEJMc1513255#SA2. Bridging Anticoagulation in Patients with Atrial Fibrillation. , , . Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2015] PMID: 26736006 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons

NEJM2016 Full Text: Link to full Text with Trip Pro